Confidential Treatment Requested As To Certain Information Contained In This Exhibit SECURITY AGREEMENT: EQUIPMENT (Dated and effective as of December 22, 2003)Security Agreement • April 30th, 2004 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances
WHEREAS, Massachusetts Development Finance Agency, a body politic and corporate and a public instrumentality under the laws of the Commonwealth of Massachusetts with its principal office at 75 Federal Street, Boston, Massachusetts 02110 (together with its successors and/or assigns, the “Lender”) has agreed to make a loan to AVANT Immunotherapeutics, Inc., a Delaware corporation with its principal office located at 119 Fourth Avenue, Needham, Massachusetts 02494 (the “Debtor”), such loan being evidenced by that certain Secured Promissory Note: Equipment Loan made by Debtor as of the date hereof to the order of the Lender (the “Note”). This Security Agreement, the Note and any UCC-1 financing statements executed in connection with this Security Agreement, as each may be amended or modified from time to time, are referred to herein, collectively, as the “Loan Documents”.
Confidential Treatment Requested As To Certain Information Contained In This ExhibitLease • April 30th, 2004 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances
Confidential Treatment Requested As To Certain Information Contained In This Exhibit NON-EXCLUSIVE LICENSE AGREEMENTNon-Exclusive License Agreement • April 30th, 2004 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • Massachusetts
This Non-Exclusive License Agreement (“Agreement”) is made and entered into this 10th day of March, 2004 (the “Effective Date”), by and between AVANT Immunotherapeutics, Inc., a Delaware corporation with offices located at 119 Fourth Avenue, Needham, Massachusetts 02494 (“AVANT”), and AdProTech Ltd., a United Kingdom company with offices located at Chesterford Research Park, Little Chesterford, Saffron Walden, Essex UK, CB10 1 XL (“LICENSEE”) (AVANT and LICENSEE sometimes hereinafter referred to as the “parties”).
